Page 38 - Read Online

Page 20 of 20 Pellerino et al. J Cancer Metastasis Treat 2020;6:41 I http://dx.doi.org/10.20517/2394-4722.2020.80

lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016;17:1683-96.
126. Gaye E, Geier M, Bore P, Guilloïque M, Lucia F, et al. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer
patient presenting leptomeningeal carcinomatosis. Lung Cancer 2019;133:1-3.
127. Califano R, Hochmair MJ, Gridelli C, Delmonte A, Camidge DR. Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.
Ann Oncol 2019;30:ii41.
128. Pellerino A, Buffoni L, Rudà R, Soffietti R. Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
Neurology 2019;93:217-9.
129. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell
lung cancer. N Engl J Med 2015;373:123-35.
130. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung
cancer. N Engl J Med 2015;373:1627-39.
131. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive,
advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
132. Barlesi F, Keunchil P, Ciardiello F, von Pawel J, Gadgeel S, et al. Primary analysis from OAK, a randomized phase III study comparing
atezolizumab with docetaxel in advanced NSCLC. ESMO 2016;LBA44-PR.
133. Hulsbergen AFC, Mammi M, Nagtegaal SHJ, Lak AM, Kavouridis V, et al. Programmed death receptor ligand one expression may
independently predict survival in patients with non-small cell lung carcinoma brain metastases receiving immunotherapy. Int J Radiat
Oncol Biol Phys 2020;S0360-3016(20)31036-1.
134. Gion MRJ, Caramella C, Soria J, Soria JC, Besse B, et al. Symptomatic leptomeningeal metastasis improvement with nivolumab in
advanced non-small celll lung cancer patient. Lung Cancer 2017;108:72-4.
135. Dudnik E, Yust-Katz S, Nechushtan H, Goldstein DA, Zer A, et al. Intracranial response to nivolumab in NSCLC patients with untreated
or progressing CNS metastases. Lung Cancer 2016;98:114-7.
136. Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, et al. Survival of patients with non-small cell lung cancer having
leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer 2019;116:182-9.
137. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, et al. Publisher correction: single-arm, open-label phase 2 trial of
pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 2020;10.1038/s41591-020-0978-1.
138. Salvador E, Shityakov S, Förster C. Glucocorticoids and endothelial cell barrier function. Cell Tissue Res 2014; 355:597-605.
139. Bebawy JF. Perioperative steroids for peritumoral intracranial edema: a review of mechanisms, efficacy, and side effects. J Neurosurg
Anesthesiol 2012;24:173-7.
140. Suzuki T, Sugimoto M, Koyama H, Mashimo T, Uchida I, et al. Inhibitory effect of glucocorticoids on human-cloned
5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology 2004;101:660-5.
141. Ho CM, Ho ST, Wang JJ, Tsai SK, Chai CY. Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth Analg
2004;99:734-9.
142. Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. Neurooncol Pract 2015;2:6-12.
143. Yin K, Li YS, Zheng MM, Jiang BY, Li WF, et al. A molecular graded prognostic assessment (molGPA) model specific for estimating
survival in lung cancer patients with leptomeningeal metastases. Lung Cancer 2019;131:134-8.